Early Management of Pulmonary Fibrosis

Initial Diagnostic Evaluation

The American Thoracic Society recommends performing HRCT as the gold standard diagnostic tool to confirm interstitial lung disease and characterize the pattern of fibrosis, as chest radiography has low added value 4, 5
The American College of Chest Physicians suggests obtaining baseline PFTs within the first evaluation, specifically measuring FVC and DLCO, which are essential for detecting disease progression and establishing treatment thresholds 4, 1
The European Respiratory Society recommends conducting a 6-minute walk test (6MWT) to evaluate both pulmonary and muscular capacity in combination, providing a holistic integrated evaluation 4

The American College of Rheumatology recommends screening for connective tissue diseases (CTD) including rheumatoid arthritis (RA), systemic sclerosis (SSc), and inflammatory myopathies, as CTD-ILD requires different management approaches than idiopathic pulmonary fibrosis 4, 2
The European League Against Rheumatism suggests assessing specific risk factors for RA-ILD: male sex, smoking history, disease duration and severity, high titers of rheumatoid factor (RF) or anti-CCP antibodies 4, 2

The American Lung Association recommends immediately addressing smoking cessation as smoking is a major risk factor for disease progression in both IPF and CTD-ILD, particularly RA-ILD 2, 5

The American Thoracic Society suggests repeating PFTs within 3 months and HRCT within 6 months of initial evaluation to determine the rate of progression in newly diagnosed patients 4
The American College of Chest Physicians recommends monitoring every 3-6 months with PFTs and clinical assessment, or sooner if clinically indicated 1, 3

The American College of Chest Physicians recommends initiating antifibrotic therapy with either pirfenidone or nintedanib immediately upon diagnosis in patients with mild-to-moderate disease (FVC ≥50% predicted, DLCO ≥30-35% predicted) 3
The European Respiratory Society suggests evaluating the balance between inflammatory and fibrotic processes to adapt anti-inflammatory and anti-fibrotic treatment appropriately 4

The American College of Rheumatology recommends initiating disease-modifying anti-rheumatic drugs (DMARDs) as first-line therapy, recognizing that the benefit/risk ratio favors their use despite rare lung toxicity concerns 4

The American Thoracic Society recommends identifying high-risk features requiring aggressive management, including UIP pattern on HRCT in RA-ILD, FVC <70% predicted or >20% disease extent on HRCT, and honeycombing on HRCT 4, 2

The American College of Chest Physicians recommends prescribing long-term oxygen therapy for patients with severe hypoxemia at rest 3
The American Thoracic Society suggests initiating pulmonary rehabilitation program for patients with significant exercise limitation, including exercise training, psychosocial support, and education 3

The American Society of Transplantation recommends providing information about lung transplantation early in the disease course, as transplantation improves survival in advanced disease 3
The International Society for Heart and Lung Transplantation suggests referring patients at increased risk of mortality at diagnosis 1, 3

The American College of Chest Physicians recommends PFTs every 4-6 months or sooner if clinically indicated 1
The American Thoracic Society suggests annual HRCT if clinical suspicion of worsening or risk of lung cancer 1